Paxil Lawsuit Over Birth Defects Results in $2.5M Award in Pennsylvania

In the first jury verdict out of more 600 Paxil lawsuits pending against GlaxoSmithKline PLC, a Pennsylvania jury has found that use of the antidepressant during pregnancy resulted in birth defects for a three year old child and awarded $2.5 million in compensation.

The decision was handed down Tuesday in the Philadelphia Court of Common Pleas, in a lawsuit was brought by the family of Lyam Kilker, whose mother, Michelle David, alleged that GlaxoSmithKline failed to adequately warn about the risk of Paxil birth defects.

Paxil (paroxetine) is a selective serotonin reuptake inhibitor prescribed to treat depression. Approved in 1992, it has become one of the most commonly prescribed drugs in the United States, with sales of just under $1 billion in 2008.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The use of Paxil during pregnancy has been linked to an increased risk of persistent pulmonary hypertension in newborns (PPHN) and other heart problems. In lawsuits pending throughout the United States, plaintiffs allege that GlaxoSmithKline hid test data and misled doctors and consumers about the risk.

In December 2005, the FDA issued an alert about the risk of birth defects from Paxil after studies showed the drug could increase the risk of the heart defects when taken during the first three months of pregnancy. At that time, the agency also required GlaxoSmithKline to update the warning label to include information about the risk of birth defects from Paxil side effects.

At trial, the plaintiffs argued that GlaxoSmithKline’s handling of the drug was outrageous, presenting internal e-mails and memos that showed scientists and executives for the drug company were aware of the Paxil birth defect side effects, even as they minimized the risk to doctors. Evidence was also introduced that suggested Glaxo aggressively promoted Paxil for use in pregnant women even after suspecting the risk.

After deliberating for seven hours, the jury awarded $2.5 million in compensatory damages, but did not award any punitive damages.

Glaxo officials maintain that they do not believe a link has been established between Paxil and Kilker’s birth defects, and said they will appeal the verdict.

2 Comments

  • AngieMarch 26, 2010 at 6:34 pm

    I was taking paxil when I became pregnant in 2003. I talked to the Dr. and slowly came off of it. My son has recently been diagnosed with epilepsy. Could this be related to the paxil during my first trimester?

  • BevJanuary 26, 2010 at 5:26 pm

    GlaxoSmithKline appears to have a terrible track records for NOT informing the dangers of many of their medications and medical devices. Being a big corporations isn't necessarily better. I hope that anyone with a legitimate suit against GSK wins big!

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted today)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.